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Background and aims: We previously demonstrated the deleterious effects of fructose feeding on 
liver through production of advanced glycation end products (AGEs) and the induction of hepatic 
steatosis and inflammation. Moreover, it has been reported that high fructose intake alters microbiota 
composition, resulting in reduced bacterial diversity and altered expression of genes involved in 
specific metabolic pathways. A recent paper demonstrated that liquid high-sugar diets compared to 
solid high-sugar diets differentially modulate intestinal sugar transporters and hormone expression. 
To date, however, the peculiar effects of intake of different forms of fructose, liquid or solid, on 
intestine integrity and microbiota, and hepatic outcomes, have never been investigated. 
Materials and methods: For this aim, C57 mice were fed a standard diet (SD) plus water to drink, 
a standard diet plus 60% fructose syrup (L-Fr), or a 60% fructose solid diet plus water (S-Fr), for 12 
weeks. At the end of protocol, analysis on liver lipogenesis, fibrosis, and inflammation were 
performed by western blotting and histological analysis. Intestinal absorption, accumulation of AGEs, 
and integrity have been assessed by immunofluorescence and histologic score. Gut microbiota 
population has been characterized by metagenomic sequencing. 
Results: L-Fr intake induced higher levels of hepatosteatosis (liver TG: +80% vs. SD, +33% vs. S-
Fr, p<0.05), with greater activation of the lipogenic SCAP/SREBP signaling, and of markers of 
fibrosis, than the S-Fr. In contrast, S-Fr evoked a stronger local AGEs accumulation, RAGE 
expression, and barrier injury in the ileum intestinal mucosa, leading to higher concentration of LPS 
in the portal plasma (+300% vs. SD, +210% vs. L-Fr, p<0.05). This effect was associated to a 
stronger activation of the LPS-dependent pro-inflammatory pathway NLRP3 inflammasome in the 
liver of S-Fr mice than of L-Fr mice. Interestingly, the local accumulation of fructose in the intestine 
led to alterations of the gut microbiota depending on the fructose formulation, with increase in the 
saccharides metabolizing Lactobacillus genus in the L-Fr, and increased colonization by populations 
related to intestinal inflammation and barrier dysruption, such as Clostridium, in the S-Fr group. 
Conclusion: These results suggest that consumption of fructose under different forms, liquid or 
solid, has a different impact on intestinal mucosa, thus differently affecting liver homeostasis. We 
hypothesize that the liquid fructose is more rapidly absorbed by intestine and metabolized by the 
liver to produce considerable amounts of lipids. In contrast, the solid form might be slowly absorbed 
by enterocytes producing glycated proteins and affecting barrier integrity, with developing of 
systemic inflammation. Such alterations of intestinal integrity and microbial population might 
predispose to the development of chronic metabolic and inflammatory diseases. 
 
